New Data Strengthen Case For RemeGen’s Telitacicept In gMG

‘Highest’ MG-ADL Response Rate

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
RemeGen has shown telitacicept's potenial as a an alternative to FcRn Inhibitors In gMG. • Source: Shutterstock

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a strong alternative to existing neonatal Fc receptor (FcRn) inhibitors in generalized myasthenia gravis (gMG), new data from a China-only Phase III study suggest.

Key Takeaways
  • RemeGen’s telitacicept looks likely to be a strong alternative to FcRn inhibitors such as argenx’s Vyvgart for generalized myasthenia gravis, based on new data from a China Phase III study.

At week 24, patients treated with telitacept subcutaneously once weekly showed improvements of a placebo-adjusted 4.8 points (p<0.001) in the...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

More from Rare Diseases

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.